Efficacy of botulinum toxin injection versus bilateral medial rectus recession for comitant esotropia: a meta-analysis

Song, Desheng; Qian, Ji; Chen, Zhijun

doi:10.1007/s00417-022-05882-5

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is still no definitive conclusion regarding the comparative effectiveness of botulinum toxin treatment versus surgery, with some studies indicating similar therapeutic outcomes for both approaches [ 83 – 85 , 88 , 89 ]. Yu et al compared the effects of BTXA injections with high-dose surgical treatment, and their two-year follow-up found that the recurrence rate in the BTXA group was significantly higher than that in the surgical group [ 87 ].…”

Section: Methodsmentioning

confidence: 99%

Advances in the diagnosis and treatment of acute acquired comitant esotropia

Guo,

Zhou,

et al. 2024

Int Ophthalmol

View full text Add to dashboard Cite

Acute acquired comitant esotropia (AACE) is mainly characterized by sudden onset, accompanied by diplopia, without extraocular muscles paralysis or ocular motility disorders. In recent years, the incidence of AACE has been increasing, researchers have found that this phenomenon may be related to the widespread use of electronic devices and the increase in the number of people working from home during the COVID-19 pandemic. However, its neural mechanisms have not been fully elucidated. This article primarily reviews the latest developments in the diagnosis and treatment of AACE from the perspectives of etiology and treatment methods, aiming to provide direction for future in-depth exploration of the pathogenesis and treatment approaches of this disease.

show abstract

Section: Methodsmentioning

confidence: 99%

Advances in the diagnosis and treatment of acute acquired comitant esotropia

Guo,

Zhou,

et al. 2024

Int Ophthalmol

View full text Add to dashboard Cite

show abstract

“…In comparative studies with surgery, similar success rates were observed in both adults and children. 44 , 45 , 46 , 47 One comparative study showed a lower success rate with BTXA, but this study included a wide range of age groups. 48 For late-onset acute comitant esotropia related to excessive screen use, the author’s first-line treatment as a golden indication is BTXA injection, while surgery is reserved for those who do not achieve a permanent cure with BTXA.…”

Section: Introductionmentioning

confidence: 99%

Golden Indications and an Overview on the Use of Botulinum Toxin in Strabismus

Özkan

2023

tjo

View full text Add to dashboard Cite

Botulinum toxin A (BTXA) is considered a pharmacological agent that may provide an alternative treatment to surgery in strabismus. It can be used as both a diagnostic and therapeutic agent in various concomitant, paralytic, and restrictive disorders. The major advantage of BTXA treatment is that it is non-invasive and does not impact the patient’s chance for future surgery in case of an unfavorable response. In some selected disorders, BTXA has become the primary choice of treatment, whereas surgery is found to be more effective in others. Accumulated knowledge and experience have demonstrated that BTXA is more than merely an alternative treatment and has additional specific indications such as in unstable deviations and as an adjunct to surgery. Patients with recurrent deviations despite multiple surgeries are also good candidates for BTXA treatment. Although the major expectation is to obtain a permanent result, BTXA can also be used as a maintenance treatment. This paper mainly focuses on the current indications for the use of BTXA in strabismology, with special emphasis on ideal first-choice applications referred to as “golden indications,” within the scope of the author’s own experience with the use of BTXA over 30 years.

show abstract